ArticlePhytotherapy research : PTR2026
Malvidin-3-O-Rhamnoside Alleviates Klebsiella pneumoniae -Induced Acute Lung Injury by Regulating Macrophage-Mediated Inflammatory and Oxidative Pathways.
Article in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Malvidin and its derivatives exhibit potent anti-inflammatory and antioxidant properties, yet their roles and mechanisms in infection-related acute lung injury (ALI) remain unclear. This study aimed to investigate the protective effects of malvidin-3-O-rhamnoside (Mv3rh) in Klebsiella pneumoniae (KP)-induced ALI and to elucidate the underlying mechanisms. A mouse model of KP-induced ALI was employed to assess the effects of Mv3rh on lung pathology, bacterial burden, myeloperoxidase (MPO) activity, alveolar macrophage proportion, cytokine levels, and survival. Mechanistic studies in alveolar macrophages included RNA sequencing, detection of reactive oxygen species (ROS), and evaluation of inflammasome activation, pyroptosis, and antioxidant responses using quantitative PCR (qPCR), Western blotting, flow cytometry, immunoprecipitation, and immunofluorescence. Potential interactions between Mv3rh with NOD-like receptor pyrin domain-containing 3 (NLRP3) or the Toll-like receptor 4/MD-2 complex were examined by molecular docking, cellular thermal shift assay (CETSA), and the interaction with TLR4 was further assessed by surface plasmon resonance (SPR). In vivo, Mv3rh pretreatment significantly mitigated KP-induced ALI, as evidenced by improved lung histopathology, reduced alveolar septal thickening, edema, and neutrophil infiltration, together with improved survival. These protective effects were accompanied by reduced systemic cytokine levels, lower bacterial burdens in the lung and blood, and partial restoration of alveolar macrophage-like cells in bronchoalveolar lavage fluid (BALF). In alveolar macrophages, Mv3rh suppressed TLR4/NF-κB signaling, reduced NLRP3 inflammasome priming and activation, inhibited cleavage of caspase-1 and GSDMD-N, and attenuated macrophage pyroptosis. In addition, Mv3rh activated the NRF2/HO-1 pathway, promoted NRF2 nuclear translocation, and restored antioxidant enzyme activities, including glutathione peroxidase (GPX), superoxide dismutase (SOD), and catalase (CAT). Mv3rh attenuates inflammation, oxidative stress, and macrophage pyroptosis in KP-induced ALI by regulating the TLR4/NF-κB/NLRP3 inflammasome axis and the NRF2/HO-1 antioxidant pathway. These findings suggest that Mv3rh possesses immunomodulatory activity and may be beneficial in KP-associated ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.